Takayoshi Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Takayoshi Sasaki has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Hiroaki Nozawa
Department of Surgical Oncology The University of Tokyo Tokyo Japan
1 shared publicationKazuhito Sasaki
Department of Surgical Oncology The University of Tokyo Tokyo Japan
1 shared publicationKoji Murono
Department of Surgical Oncology The University of Tokyo Tokyo Japan
1 shared publicationShigenobu Emoto
Department of Surgical Oncology The University of Tokyo Tokyo Japan
1 shared publication- Shinya Abe
Department of Surgical Oncology, Graduate School of Medicine The University of Tokyo Bunkyo‐ku Tokyo Japan
1 shared publication Soichiro Ishihara
Department of Surgical Oncology The University of Tokyo Tokyo Japan
1 shared publication
Latest Publications
- Open Access
- 8 March 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1097-1106
Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis
Aim: A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown. Methods: This study reviewed 352 patients with rectal cancer who received preoperative chemoradiotherapy between 2003 and 2023. The cut‐off value for the pre‐treatment NM value was established at the median. A pre‐treatment size of lateral lymph node (LLN) ≥ 8 mm was defined as clinical LLN metastasis. The prognostic significance of the NM value was evaluated. Results: The cut‐off NM value was 1 100 000; 179 patients had an NM value ≥ 1 100 000. Ninety‐nine patients had LLN ≥ 8 mm. Disease‐free survival (DFS) was significantly shorter in patients with an NM value ≥ 1 100 000 than in those with an NM value < 1 100 000. DFS and overall survival (OS) were shorter in patients with LLN ≥ 8 mm than in those with LLN < 8 mm. The LLN size and NM value were identified as independent prognostic factors for DFS (LLN size—hazard ratio (HR): 1.51, p = 0.04, NM value—HR: 1.53, p = 0.04). Patients with LLN ≥ 8 mm and an NM value ≥ 1 100 000 had the poorest prognosis among the populations compared by the combination of LLN size and NM value. Conclusions: The pre‐treatment NM value is an independent prognostic factor associated with DFS. In patients with LLN ≥ 8 mm, a high NM value may be a significant indicator of a poor prognosis.
- 8 March 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1097-1106
Open AccessRelationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis
Aim: A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown. Methods: This study reviewed 352 patients with rectal cancer who received preoperative chemoradiotherapy between 2003 and 2023. The cut‐off value for the pre‐treatment NM value was established at the median. A pre‐treatment size of lateral lymph node (LLN) ≥ 8 mm was defined as clinical LLN metastasis. The prognostic significance of the NM value was evaluated. Results: The cut‐off NM value was 1 100 000; 179 patients had an NM value ≥ 1 100 000. Ninety‐nine patients had LLN ≥ 8 mm. Disease‐free survival (DFS) was significantly shorter in patients with an NM value ≥ 1 100 000 than in those with an NM value < 1 100 000. DFS and overall survival (OS) were shorter in patients with LLN ≥ 8 mm than in those with LLN < 8 mm. The LLN size and NM value were identified as independent prognostic factors for DFS (LLN size—hazard ratio (HR): 1.51, p = 0.04, NM value—HR: 1.53, p = 0.04). Patients with LLN ≥ 8 mm and an NM value ≥ 1 100 000 had the poorest prognosis among the populations compared by the combination of LLN size and NM value. Conclusions: The pre‐treatment NM value is an independent prognostic factor associated with DFS. In patients with LLN ≥ 8 mm, a high NM value may be a significant indicator of a poor prognosis.